- Home
- TCBS vs IFRX Comparison
TCBS vs IFRX Comparison
Compare TCBS & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCBS
- IFRX
- Stock Information
- Founded
- TCBS 1934
- IFRX 2007
- Country
- TCBS United States
- IFRX Germany
- Employees
- TCBS N/A
- IFRX N/A
- Industry
- TCBS Banks
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- TCBS Finance
- IFRX Health Care
- Exchange
- TCBS Nasdaq
- IFRX Nasdaq
- Market Cap
- TCBS 48.7M
- IFRX 53.5M
- IPO Year
- TCBS N/A
- IFRX 2017
- Fundamental
- Price
- TCBS $15.98
- IFRX $0.88
- Analyst Decision
- TCBS
- IFRX Strong Buy
- Analyst Count
- TCBS 0
- IFRX 4
- Target Price
- TCBS N/A
- IFRX $7.75
- AVG Volume (30 Days)
- TCBS 3.3K
- IFRX 210.3K
- Earning Date
- TCBS 08-01-2025
- IFRX 08-07-2025
- Dividend Yield
- TCBS 1.01%
- IFRX N/A
- EPS Growth
- TCBS N/A
- IFRX N/A
- EPS
- TCBS 0.80
- IFRX N/A
- Revenue
- TCBS $14,831,000.00
- IFRX $191,224.00
- Revenue This Year
- TCBS N/A
- IFRX N/A
- Revenue Next Year
- TCBS N/A
- IFRX $1,276.37
- P/E Ratio
- TCBS $19.83
- IFRX N/A
- Revenue Growth
- TCBS 51.57
- IFRX 54.36
- 52 Week Low
- TCBS $13.70
- IFRX $0.71
- 52 Week High
- TCBS $19.40
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- TCBS 50.47
- IFRX 52.76
- Support Level
- TCBS $15.86
- IFRX $0.78
- Resistance Level
- TCBS $15.95
- IFRX $0.86
- Average True Range (ATR)
- TCBS 0.06
- IFRX 0.07
- MACD
- TCBS 0.01
- IFRX 0.01
- Stochastic Oscillator
- TCBS 70.00
- IFRX 67.51
About TCBS Texas Community Bancshares Inc.
Texas Community Bancshares Inc is a holding company. The company's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank of Dallas, in residential real estate loans and commercial real estate loans and, to a lesser extent, commercial loans, construction and land loans, and consumer and other loans. Its portfolio segments are real estate, agriculture, commercial, consumer and other.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.